Digestive Tract Tumors
Conditions
Interventions
Observation group:None
Sponsors
The First Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients must meet the following criteria to be enrolled in this study: 2.Patients sign an informed consent form to voluntarily enroll in this study; 3.Pathologically or histocytologically confirmed diagnosis of gastric, colorectal, pancreatic, or esophageal cancer; 4.Patients receiving irinotecan hydrochloride liposome injection II based therapy (chemotherapy combined with radiotherapy, targeted therapy, immunotherapy, etc.) ; 5.Patients with >= 12 weeks of survival ; 6.Age >= 18 years.
Exclusion criteria
Exclusion criteria: 1.Enrollment in this study is prohibited if the patient has any of the following: 2.Pregnant or lactating females; 3.Hypersensitivity to treatment with irinotecan hydrochloride liposome injection II; 4.Subjects who have already been discharged from this study; 5.Other conditions that, in the judgment of the investigator, make inclusion in the study unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival ;Progression-free survival;Time to Progress;Objective response rate;Disease control rate; | — |
Countries
China
Contacts
Public ContactYusheng Wang
The First Hospital of Shanxi Medical University
Outcome results
None listed